Compounds of Formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof; processes and intermediates for preparation thereof, compositions thereof, and uses thereof; are provided. Pharmaceutical compositions comprising a compound of Formula I, or enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof; wherein the compound is a double and/or triple agent or ligand for CYP2D6, 5-HT2A, and/or 5HT2C receptors, and/or acetylcholinesterase are provided. ##STR00001##

A method for treating a subject with depression characterized by having an increased burst firing in neurons of a lateral habenula in the subject is provided. The method includes a step of administering to the subject a pharmaceutical composition capable of inhibiting the burst firing in the lateral habenula of the subject. The pharmaceutical composition includes one or more active pharmaceutical agents, which can suppress the burst firing in the lateral habenula of the subject and can include at least one of an N-methyl-D-aspartate receptor (NMDAR) inhibitor or a T-type calcium channel inhibitor. The pharmaceutical composition can be in a formulation allowing for local administration to the lateral habenula of the subject, or can be in a formulation configured for systemic administration to the subject. A method for testing a test substance for an antidepressive effect is also provided.

A method for treating a subject with depression characterized by having an increased burst firing in neurons of a lateral habenula in the subject is provided. The method includes a step of administering to the subject a pharmaceutical composition capable of inhibiting the burst firing in the lateral habenula of the subject. The pharmaceutical composition includes one or more active pharmaceutical agents, which can suppress the burst firing in the lateral habenula of the subject and can include at least one of an N-methyl-D-aspartate receptor (NMDAR) inhibitor or a T-type calcium channel inhibitor. The pharmaceutical composition can be in a formulation allowing for local administration to the lateral habenula of the subject, or can be in a formulation configured for systemic administration to the subject. A method for testing a test substance for an antidepressive effect is also provided.

The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.

The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.

The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.

The invention provides a composition comprising methylphosphonic acid or a salt thereof for human consumption. The invention also provides a method for treating aging and/or improving health in a human. Methods of the invention involve providing or administering methylphosphonic acid or a salt thereof to a human in need thereof for consumption. The invention provides nutritional and pharmaceutical compositions and articles containing such compositions including, for example, a nutritional supplement, a beverage, a food substance, a prepackaged food or meal, or a nutraceutical, as well as a pharmaceutical.

The invention provides a composition comprising methylphosphonic acid or a salt thereof for human consumption. The invention also provides a method for treating aging and/or improving health in a human. Methods of the invention involve providing or administering methylphosphonic acid or a salt thereof to a human in need thereof for consumption. The invention provides nutritional and pharmaceutical compositions and articles containing such compositions including, for example, a nutritional supplement, a beverage, a food substance, a prepackaged food or meal, or a nutraceutical, as well as a pharmaceutical.

The invention comprises an agent for use in medicine, wherein the agent comprises a compound of Formula (I): B-L-B′ wherein: B and B′ are independently selected from groups of formula (B-I) wherein: Z is selected from —COOH, —CH.sub.2COOH, —PO(OH)(OR.sup.1), or —CH.sub.2PO(OH) (OR.sup.1), wherein R.sup.1 is H or a phosphate protecting group; W is an alicyclic amine group having from 5 to 12 carbon atoms and at least one amine nitrogen atom; W′ is H, or W′ is linked to W to form said alicyclic amine group; and Y is selected from —NH—, —N(CH.sub.3)—, —CH.sub.2—, —NHCO—, —CH.sub.2CONH—, —CONH—, CH.sub.2NHCO—, or —NHCH.sub.2—; and L is a linker group.

##STR00001##

The invention comprises an agent for use in medicine, wherein the agent comprises a compound of Formula (I): B-L-B′ wherein: B and B′ are independently selected from groups of formula (B-I) wherein: Z is selected from —COOH, —CH.sub.2COOH, —PO(OH)(OR.sup.1), or —CH.sub.2PO(OH) (OR.sup.1), wherein R.sup.1 is H or a phosphate protecting group; W is an alicyclic amine group having from 5 to 12 carbon atoms and at least one amine nitrogen atom; W′ is H, or W′ is linked to W to form said alicyclic amine group; and Y is selected from —NH—, —N(CH.sub.3)—, —CH.sub.2—, —NHCO—, —CH.sub.2CONH—, —CONH—, CH.sub.2NHCO—, or —NHCH.sub.2—; and L is a linker group.

##STR00001##